Bausch Health Companies (NYSE:BHC) Downgraded by ValuEngine to “Strong Sell”
Bausch Health Companies (NYSE:BHC) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday, ValuEngine reports.
Other research analysts have also issued research reports about the stock. Bank of America upped their price target on shares of Altria Group from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Barclays upped their price target on shares of from GBX 7,500 ($98.00) to GBX 8,100 ($105.84) and gave the company an “overweight” rating in a research note on Monday. Piper Jaffray Companies set a $29.00 price target on shares of Bausch Health Companies and gave the company a “buy” rating in a research note on Tuesday, June 11th. JPMorgan Chase & Co. upped their price target on shares of Vermilion Energy from C$42.00 to C$43.00 in a research note on Monday, May 13th. Finally, Cantor Fitzgerald set a $32.00 price target on shares of Bausch Health Companies and gave the company a “buy” rating in a research note on Friday, May 31st. Three analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. Bausch Health Companies has a consensus rating of “Hold” and a consensus target price of $27.65.
Shares of NYSE BHC traded down $0.26 during trading hours on Friday, hitting $23.61. 2,967,100 shares of the stock were exchanged, compared to its average volume of 4,083,662. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. The firm has a market capitalization of $8.38 billion, a P/E ratio of 5.87, a PEG ratio of 0.56 and a beta of 0.78. The firm’s fifty day simple moving average is $23.17. Bausch Health Companies has a 12 month low of $17.20 and a 12 month high of $28.45.
A number of institutional investors have recently modified their holdings of the business. Orbimed Advisors LLC raised its holdings in Bausch Health Companies by 89.1% in the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after acquiring an additional 1,696,400 shares during the last quarter. Bessemer Group Inc. purchased a new stake in Bausch Health Companies in the 4th quarter worth approximately $33,000. Highstreet Asset Management Inc. purchased a new stake in Bausch Health Companies in the 1st quarter worth approximately $354,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Bausch Health Companies by 1.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 193,792 shares of the company’s stock worth $4,783,000 after buying an additional 2,223 shares in the last quarter. Finally, CLARET ASSET MANAGEMENT Corp lifted its position in Bausch Health Companies by 9.2% in the 1st quarter. CLARET ASSET MANAGEMENT Corp now owns 14,751 shares of the company’s stock worth $364,000 after buying an additional 1,245 shares in the last quarter. Institutional investors and hedge funds own 53.67% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Read More: Are FAANG stocks a good investment?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.